Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS4XFI)

Drug Name

OPT-302 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Vascular endothelial growth factor C (VEGFC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VGX-100	DM9GC4R	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting Vascular endothelial growth factor D (VEGFD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
EG-016	DM7JMVR	Peripheral vascular disease	BD4Z	Discontinued in Phase 1/2	[4]
EG-011	DM17GMN	Angina pectoris	BA40	Discontinued in Phase 1/2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor C (VEGFC)	TT0QUFV	VEGFC_HUMAN	Inhibitor	[2]
Vascular endothelial growth factor D (VEGFD)	TTOM5H4	VEGFD_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03345082) A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Opthea.
3	National Cancer Institute Drug Dictionary (drug id 724066).
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030807)